n Cardiovascular Journal of South Africa - Outcomes data for Atacand(R) : results of the SCOPE study : drug trends in cardiology




Extracted from text ... Outcomes data for Atacand(r): Results of the SCOPE study SCOPE compared treatment with Atacand(r) (candesartan cilexetil) to other antihypertensive therapy over a 3- to 5-year period in 4 964 elderly patients (over 70 years of age) with hypertension. Although originally planned as a placebo controlled study, additional antihypertensive medication was added to both the Atacand(r) and placebo groups if pre-specified BP targets were not reached at the study visits. Eighty-four per cent of the patients enrolled into the placebo group and 75% of the Atacand(r) group received add-on medication. The primary endpoint was reduction of major cardiovascular events (cardiovascular death, ..


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error